Skip to main content
S&P 5007,520.93-0.38%DOW52,231.89-0.30%NASDAQ25,065.88-0.74%BTC$73,671.00-1.77%ETH$2,057.29-3.16%GOLD$4,059.70+0.73%OIL$86.26+0.26%
Smart Investors Daily
SID Premium
HI

NYSE · HIMS

Hims & Hers Health, Inc.

Healthcare · Medical - Equipment & Services

$19.13

Down-$3.81 (-16.59%)

Updated Nov 11, 2026, 5:45 AM

SID Score

3.2/10

Composite research score

Smart Money

54/100

Neutral

Market cap
8.28B
P/E ratio
63.9
Dividend yield
0.00%
52-week range
$13.74 – $42.70
Volume
58.76M
Avg. volume
27.1M

Price performance · HIMS

HIMS price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 10, 2026

HIMS closed at $19.13 after 21 trading sessions, down 35.61% for the selected period.

Last close
$19.13
Period change
-35.61%
Period low
$19.13
Period high
$29.71
Daily close
View OHLC price history
HIMS OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 10, 2026$22.12$22.47$18.4001$19.1358.76M
Nov 9, 2026$25.25$25.67$22.73$22.9450.15M
Nov 6, 2026$25.78$26.24$24.405$26.0013.17M
Nov 5, 2026$26.25$26.5699$22.88$24.0617.59M
Nov 4, 2026$25.92$28.66$25.92$26.6611.64M
Nov 3, 2026$25.48$26.37$25.40$25.707.43M
Nov 2, 2026$27.97$28.49$25.145$25.2410.79M
Oct 30, 2026$28.51$28.7497$26.68$27.6810.86M
Oct 29, 2026$29.26$30.13$28.66$29.677.52M
Oct 28, 2026$27.71$29.805$27.60$29.3212.28M
Oct 27, 2026$27.99$28.465$27.59$27.927.5M
Oct 26, 2026$27.51$27.94$27.22$27.595.76M
Oct 23, 2026$28.85$28.905$27.30$27.719.83M
Oct 22, 2026$28.64$29.26$27.98$29.138.47M
Oct 21, 2026$29.38$29.92$28.85$29.216M
Oct 20, 2026$28.00$30.02$27.75$29.2110.55M
Oct 19, 2026$28.49$29.00$27.53$28.157.49M
Oct 16, 2026$29.51$30.00$27.53$28.0711.02M
Oct 15, 2026$26.875$29.65$26.33$29.3816.31M
Oct 14, 2026$29.26$29.6799$27.565$27.7211.07M
Oct 13, 2026$29.83$30.3822$28.7248$29.719.78M

Latest HIMS news

The latest Smart Investors Daily articles mentioning HIMS.

Stock researchCompany · Overview

HIMS research

Overview

Company profile and research snapshot.

Company profile

Hims & Hers, launched in 2017, is a telehealth platform that connects patients and healthcare providers to offer treatment options for specialties like erectile dysfunction, hair loss, skin care, mental health, and weight loss. Its offerings include generic, branded, and compounded prescription drugs as well as over-the-counter medicines, cosmetics, and supplements. The platform, which has more than 2 million subscribers, is available in all 50 states and certain European markets like the UK. It includes provider networks, electronic medical records, cloud pharmacy fulfillment, and personalization capabilities. Hims does not take insurance and only accepts payments directly from customers.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$42.83
Implied upside
—
Analysts
—
HIMS recent ratings
DateFirmRatingTarget
Nov 10, 2026Morgan StanleyEqual-Weight—
Nov 10, 2026Evercore ISI GroupIn-Line—
Nov 10, 2026NeedhamBuy—
Aug 24, 2026Truist SecuritiesHold—
Aug 21, 2026BarclaysOverweight—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Nov 7, 2026

Hims & Hers Health (HIMS) Could Be 85% Undervalued Following The Eli Lilly Deal

Hims & Hers Health (HIMS) just signed a new agreement with Eli Lilly that allows its users to access branded obesity drugs Zepbound and Foundayo directly through the telehealth platform, including integrated consultations and home delivery. Investor reaction has been mixed in the run up to this Eli Lilly deal, with the 1 day share price return of 8.06% contrasting with a 30 day share price return down 11.98% and a year to date share price return down 22.18%. Capitalize on the renewed focus...

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By